drugset / Trial / NCT00188604

The Use of Selenium to Treat Secondary Lymphedema - Breast Cancer

NCT00188604

RandomizedCrossoverDouble-blindTreatment

Summary

The primary objective of this study to assess the effectiveness of selenium compared to placebo in reducing the lymphedema in-patients with breast cancer. Secondary objectives are to assess the impact of selenium on patient's quality of life and to assess the incidence of adverse effects of selenium therapy.

Timeline

Start
2004-01
Primary completion
2009-01
Completion
2009-01

Drugs

EvaluationDrugModalityDoseRoute
Subject sodium selenite Unknown